NYVEPRIA

This brand name is authorized in Austria, Canada, Croatia, Estonia, France, Ireland, Italy, Lithuania, Poland, Spain.

Active ingredients

The drug NYVEPRIA contains one active pharmaceutical ingredient (API):

1	Pegfilgrastim UNII 3A58010674 - PEGFILGRASTIM
	Pegfilgrastim is a sustained duration form of filgrastim due to decreased renal clearance. Pegfilgrastim and filgrastim have been shown to have identical modes of action, causing a marked increase in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes and/or lymphocytes.
	Read more about Pegfilgrastim

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
NYVEPRIA Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L03AA13	Pegfilgrastim	L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants → L03AA Colony stimulating factors
Discover more medicines within L03AA13

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02506238
EE	Ravimiamet	1833544
ES	Centro de información online de medicamentos de la AEMPS	1201486001
FR	Base de données publique des médicaments	68698437
IT	Agenzia del Farmaco	049200013
LT	Valstybinė vaistų kontrolės tarnyba	1091343
PL	Rejestru Produktów Leczniczych	100444550